Comprehensive genetic testing for advanced lung cancer
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11179330
This project looks at how using wide genetic testing that checks hundreds of cancer genes might help people with advanced non-small cell lung cancer and influence care decisions and costs.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11179330 on ClinicalTrials.gov |
What this research studies
If you have advanced lung cancer, researchers will use real-world medical records and claims data to see who gets broad genomic profiling, why doctors order it, and how results change treatment choices. They will combine data from Medicare and other contemporary U.S. datasets to track outcomes, treatment patterns, and costs after testing. The team will apply value-of-information methods to estimate whether doing more research would meaningfully reduce uncertainty and improve decisions about using broad genomic testing. Findings are meant to inform clinicians, patients, insurers, and policymakers about the practical benefits and trade-offs of routine broad genomic testing.
Who could benefit from this research
Good fit: People with advanced non-small cell lung cancer receiving care in the United States are the main group whose care patterns and outcomes are studied.
Not a fit: People without advanced lung cancer, those with early-stage disease, or patients whose tumors lack actionable mutations likely would not directly benefit from this work.
Why it matters
Potential benefit: Could help more patients be matched to targeted treatments and guide decisions about when broad genomic testing is worth using.
How similar studies have performed: Previous work shows broad genomic profiling often finds actionable mutations and can guide targeted therapy, but evidence on long-term outcomes and cost-effectiveness is still evolving.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GROSS, CARY P. — YALE UNIVERSITY
- Study coordinator: GROSS, CARY P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, Cancer Treatment, Cancers